United States · 
Who invested in Progentos Therapeutics?
Progentos Therapeutics's investors include Forbion Capital Partners, Longwood Fund and Mission BioCapital.
United States · Series A startup
Who invested in Progentos Therapeutics
Funding summaryUpdated 26 Oct 2026
$65Mraised across 1 round since 2024, from 1 source
- Latest round
- Series A, $65MMay 2024
- Investors
- 3
The rounds
- May 2024Series A$65M
Source recordedSEC filing: $69M sold, first sale May 2024
Founders and team
From Progentos Therapeutics's own website and the SEC filings it signed: 2 founders, 7 on the team.
Chris LooseCo-Founder/CEO
Sanjay MagaviCo-Founder/CSONamed on its 2024 Form D
- Andrew MillerChairman of the Board
- Marc-Oliver TurgeonBoard Member
- Aleks Radovic-MorenoBoard Member
- Cassidy BlundellBoard Member
- Christopher LooseExecutive Officer, Directori
- Dan JanneyBoard Member
- Dmitrij HristodorovBoard Member
On the board, as filediMarc-Olivier Turgeon
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about Progentos Therapeutics
How much has Progentos Therapeutics raised?
Progentos Therapeutics has raised $65M across 1 round since 2024.
When did Progentos Therapeutics last raise?
Progentos Therapeutics's most recent round was a Series A of $65M in May 2024.
What was Progentos Therapeutics's biggest round?
Its most recent round, $65M in May 2024, is also its largest on record.
Who backed Progentos Therapeutics first?
Progentos Therapeutics's first round on record, in May 2024, was backed by Forbion Capital Partners, Longwood Fund and Mission BioCapital.
What stage is Progentos Therapeutics at?
Progentos Therapeutics's latest named round is a Series A, in May 2024.
Where is Progentos Therapeutics based?
Progentos Therapeutics is based in the United States.
Companies like Progentos Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.